Literature DB >> 2109098

Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.

A Aldovini1, R A Young.   

Abstract

To identify RNA and protein sequences involved in packaging of human immunodeficiency virus type 1 (HIV-1), various mutations were introduced into the viral genome. Portions of the human immunodeficiency virus type 1 genome between the first splice donor site and the gag initiation codon were deleted to investigate the RNA packaging site (psi). Point mutations that alter cysteine residues in one or both zinc finger motifs of p7, a cleavage product of the gag precursor, were created to study the role of the gag zinc fingers in packaging. The psi site mutants and the gag mutants exhibited similar phenotypes. Cells transfected with the mutant genomes, while expressing normal levels of human immunodeficiency virus type 1 RNA and proteins, produced viral particles that were normal in protein content but lacked detectable viral RNA. These mutant virions were unable to productively infect cells. The combination of human immunodeficiency virus type 1 packaging mutations should minimize fortuitous assembly of infectious virus and may provide a means to produce noninfectious particles for candidate vaccines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109098      PMCID: PMC249345     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Mutations in Rous sarcoma virus nucleocapsid protein p12 (NC): deletions of Cys-His boxes.

Authors:  C Méric; E Gouilloud; P F Spahr
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  A conserved cis-acting sequence in the 5' leader of avian sarcoma virus RNA is required for packaging.

Authors:  R A Katz; R W Terry; A M Skalka
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein.

Authors:  C Méric; S P Goff
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biochemical properties of mutant TK15 and mutant-induced transformants.

Authors:  T Koyama; F Harada; S Kawai
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

9.  Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence.

Authors:  R J Gorelick; L E Henderson; J P Hanser; A Rein
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

View more
  274 in total

1.  Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.

Authors:  C Liang; L Rong; Y Quan; M Laughrea; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Deletion mutagenesis downstream of the 5' long terminal repeat of human immunodeficiency virus type 1 is compensated for by point mutations in both the U5 region and gag gene.

Authors:  C Liang; L Rong; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.

Authors:  B Berkhout; J L van Wamel
Journal:  RNA       Date:  2000-02       Impact factor: 4.942

4.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Authors:  S Druillennec; C Z Dong; S Escaich; N Gresh; A Bousseau; B P Roques; M C Fournié-Zaluski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

6.  Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 7.  Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Authors:  R J Miller; J S Cairns; S Bridges; N Sarver
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Role of RNA in facilitating Gag/Gag-Pol interaction.

Authors:  Ahmad Khorchid; Rabih Halwani; Mark A Wainberg; Lawrence Kleiman
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Experimental determination and calculations of redox potential descriptors of compounds directed against retroviral zinc fingers: Implications for rational drug design.

Authors:  I A Topol; C McGrath; E Chertova; C Dasenbrock; W R Lacourse; M A Eissenstat; S K Burt; L E Henderson; J R Casas-Finet
Journal:  Protein Sci       Date:  2001-07       Impact factor: 6.725

10.  Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA.

Authors:  Rodney S Russell; Jing Hu; Véronique Bériault; Andrew J Mouland; Michael Laughrea; Lawrence Kleiman; Mark A Wainberg; Chen Liang
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.